# Antibiotic overuse as a modifiable early-life risk factor for non-communicable diseases in sub-Saharan Africa

**Authors:** Michelle Leal, Johanni Beukes, Stephanie Alcock, Urlridge Thompson, Shane A. Norris

PMC · DOI: 10.1080/16549716.2026.2646042 · 2026-03-18

## TL;DR

Early-life antibiotic overuse in sub-Saharan Africa is linked to increased risk of non-communicable diseases and needs better policy integration.

## Contribution

This paper reframes early-life antibiotic exposure as a modifiable health determinant by bridging antimicrobial resistance and NCD prevention strategies.

## Key findings

- Early-life antibiotic use in sub-Saharan Africa is widespread and linked to rising non-communicable disease risks.
- Health systems can address both antimicrobial resistance and NCDs by integrating antibiotic tracking into child health platforms.

## Abstract

Early-life antibiotic overuse is a public health concern. In low- and middle-income countries, consumption has surged by 76% since 2000. This trend is particularly acute in sub-Saharan Africa (SSA), where antimicrobial resistance contributes to 255,000 deaths annually and infant antibiotic exposure is widespread in the first two years of life. While a substantial body of research associates antibiotic-induced microbiome disruption with metabolic and immune dysregulation, with large cohorts reporting ~20% higher odds of childhood obesity and asthma, these observational findings do not establish causality and derive largely from high-income settings. This potential pathway remains a policy blind spot within most non-communicable disease (NCD) prevention frameworks. By synthesising biological, epidemiological and implementation evidence, this paper considers early-life antibiotic exposure as a potentially modifiable determinant of lifelong health and outlines a pragmatic research and policy agenda to integrate antibiotic-aware prevention into NCD prevention efforts and routine child health platforms in resource-limited SSA settings.

Main findings: Pervasive early-life antibiotic use, driven by rising consumption in LMICs and limited stewardship in sub-Saharan Africa, represents a significant and underappreciated driver of non-communicable disease risk.

Added knowledge: This paper bridges the policy gap between strategies to contain antimicrobial resistance and strategies to prevent chronic non-infectious diseases, by synthesising mechanistic, epidemiological and implementation evidence to reframe early-life antibiotic exposure as a primary, modifiable determinant of lifelong health.

Global health impact for policy and action: Health systems can address the dual burden of antimicrobial resistance and chronic non-infectious diseases by integrating antibiotic-aware risk profiling into routine child health, using existing platforms to track exposure and deliver targeted preventive interventions in high-burden settings.

## Linked entities

- **Diseases:** asthma (MONDO:0004979)

## Full-text entities

- **Genes:** GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}
- **Diseases:** eczema (MESH:D004485), chronic respiratory disease (MESH:D012140), immune dysregulation (OMIM:614878), asthma (MESH:D001249), cardiovascular disease (MESH:D002318), infectious (MESH:D003141), allergic airway inflammation (MESH:D007249), stunted (MESH:D006130), allergic conditions (MESH:D004342), SSA (MESH:D000073605), AMR (MESH:D060467), adiposity (MESH:D018205), diabetes (MESH:D003920), immune-mediated disorders (MESH:C567355), infections (MESH:D007239), Insulin Resistance (MESH:D007333), NCD (MESH:D000073296), metabolic (MESH:D008659), dysregulation (MESH:D021081), DOHaD (OMIM:603663), obesity (MESH:D009765), cancer (MESH:D009369), malnutrition (MESH:D044342), deaths (MESH:D003643), overweight (MESH:D050177)
- **Chemicals:** ceftriaxone (MESH:D002443), lipopolysaccharide (MESH:D008070), butyrate (MESH:D002087), lipid (MESH:D008055), beta-lactam (MESH:D047090), glucose (MESH:D005947), short-chain fatty acid (MESH:D005232), amoxicillin - clavulanate (MESH:D019980), cephalosporin (MESH:D002511), metronidazole (MESH:D008795), bile acid (MESH:D001647), penicillin (MESH:D010406), vancomycin (MESH:D014640)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606], Bifidobacterium (genus) [taxon 1678], Mus musculus (house mouse, species) [taxon 10090], Faecalibacterium prausnitzii (species) [taxon 853]

---
Source: https://tomesphere.com/paper/PMC13003843